**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 61397

**Manuscript Type:** CASE REPORT

**Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report**

Yasuma T *et al*. Fulminant diabetes and ketoacidosis

Taro Yasuma, Yuko Okano, Soichiro Tanaka, Kota Nishihama, Kazuhito Eguchi, Chisa Inoue, Kanako Maki, Akihiro Uchida, Mei Uemura, Toshinari Suzuki, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Yutaka Yano

**Taro Yasuma, Yuko Okano,** Department of Diabetes, Metabolism, and Endocrinology and Immunology, Mie University, Tsu 514-8507, Japan

**Soichiro Tanaka, Kota Nishihama, Kazuhito Eguchi, Chisa Inoue, Kanako Maki, Akihiro Uchida, Mei Uemura, Toshinari Suzuki,** Department of Diabetes, Metabolism, and Endocrinology, Mie University, Tsu 514-8507, Japan

**Corina N D'Alessandro-Gabazza,** Department of Immunology, Mie University School of Medicine, Mie University, Tsu 514-8507, Japan

**Esteban C Gabazza,** Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan

**Yutaka Yano,** Department of Diabetes, Mie University Graduate School of Medicine, Tsu 514-8507, Japan

**Author contributions:** Yasuma T, Tanaka S, and Nishihama K were responsible for clinical treatment and clinical follow-up; Yasuma T prepared the first draft of the manuscript; Eguchi KC, Inoue CC, Maki KC, Okano Y, and Uchida A contributed with resources and acquisition of data; Suzuki T, D'Alessandro-Gabazza CN, Yano Y, and Gabazza EC contributed to the interpretation of the data and made an intellectual contribution to the manuscript's preparation.

**Corresponding author: Esteban C Gabazza, MD, PhD, Director, Full Professor,** Department of Immunology, Mie University Faculty and Graduate School of Medicine, Edobashi 2-174, Tsu 514-8507, Japan. gabazza@doc.medic.mie-u.ac.jp

**Received:** December 8, 2020

**Revised:** January 26, 2021

**Accepted:** March 11, 2021

**Published online:** May 6, 2021

**Abstract**

BACKGROUND

Fulminant type 1 diabetes mellitus (FT1DM) is a subtype of type 1 diabetes mellitus characterized by an abrupt onset and a rapid and complete functional loss of islet β cells. It is a very rare disease generally associated with ketoacidosis and the absence of circulating pancreatic islet-related autoantibodies. Diabetic ketoacidosis with normal blood glucose levels has been reported during sodium-glucose co-transporter 2 (SGLT2) inhibitor therapy.

CASE SUMMARY

The patient was a 43-year-old woman that consulted a medical practitioner for malaise, thirst, and vomiting. Blood analysis showed high blood glucose levels (428 mg/dL), a mild increase of hemoglobin A1c (6.6%), and increased ketone bodies in urine. The patient was diagnosed with type 2 diabetes mellitus. The patient was initially treated with insulin, which was subsequently changed to an oral SGLT2 inhibitor. Antibodies to glutamic acid decarboxylase were negative. Four days after receiving oral SGLT2 inhibitor, she consulted at Mie University Hospital, complaining of fatigue and vomiting. Laboratory analysis revealed diabetic ketoacidosis with almost normal blood glucose levels. The endogenous insulin secretion was markedly low, and the serum levels of islet-related autoantibodies were undetectable. We made the diagnosis of FT1DM with concurrent SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis. The patient's general condition improved after therapy with intravenous insulin and withdrawal of oral medication. She was discharged on day 14 with an indication of multiple daily insulin therapy.

CONCLUSION

This patient is a rare case of FT1DM that developed SGLT2 inhibitor-associated diabetic ketoacidosis with almost normal blood glucose levels. This case report underscores the importance of considering the diagnosis of FT1DM in patients with negative circulating autoantibodies and a history of hyperglycemia that subsequently develop euglycemic diabetic ketoacidosis following treatment with a SGLT2 inhibitor.

**Key Words:** Euglycemic diabetic ketoacidosis; Sodium-glucose cotransporter 2 inhibitors; Fulminant type 1 diabetes; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, Maki K, Uchida A, Uemura M, Suzuki T, D'Alessandro-Gabazza CN, Gabazza EC, Yano Y. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. *World J Clin Cases* 2021; 9(13): 3163-3169 URL: https://www.wjgnet.com/2307-8960/full/v9/i13/3163.htm DOI: https://dx.doi.org/10.12998/wjcc.v9.i13.3163

**Core Tip:** Fulminant type 1 diabetes mellitus (FT1DM) is characterized by a rapid functional loss of islet β cells and ketoacidosis. Herein, we report a rare case of FT1DM wrongly diagnosed by a medical practitioner as a type 2 diabetes mellitus for the absence of circulating autoantibodies and treated with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor. This treatment was associated with diabetic symptoms and euglycemic diabetic ketoacidosis. Insulin therapy and SGLT2 inhibitor withdrawal ameliorated the patient's clinical condition. This case report underscores the importance of considering FT1DM in patients with negative circulating autoantibodies and hyperglycemia that develop euglycemic diabetic ketoacidosis during SGLT2 inhibitor treatment.

**INTRODUCTION**

Fulminant type 1 diabetes mellitus (FT1DM) is a rare subtype of type 1 diabetes mellitus[1]. Abrupt onset of the disease with a rapid and complete loss of islet β cell function is a characteristic finding of FT1DM[1]. Although this metabolic disorder's clinical manifestations are nonspecific, it can lead to diabetic ketoacidosis and increase death risk if not promptly diagnosed and treated with insulin[1]. Unlike patients with acute-onset type 1 diabetes mellitus, patients with FT1DM are negative for circulating pancreatic islet-related autoantibodies[1]. Therapy with sodium-glucose co-transporter 2 (SGLT2) inhibitor may trigger diabetic ketoacidosis with normal blood glucose levels. Here, we report a case of diabetic ketoacidosis with almost normal blood glucose levels following therapy with SGLT2 inhibitor that prompted the diagnosis of FT1DM.

**CASE PRESENTATION**

***Chief complaints***

The patient was a 43-year-old woman that consulted the Mie University Hospital because of fatigue and vomiting.

***History of present illness***

The patient first consulted a medical practitioner because of sudden malaise, thirst, and vomiting in April 2019. A laboratory analysis disclosed increased blood glucose levels (428 mg/dL), a mild increase of hemoglobin A1c (6.6%), and increased ketone bodies in urine. She received insulin therapy for four days. Because the serum anti-glutamic acid decarboxylase antibody was negative, she was diagnosed with type 2 diabetes mellitus. The treatment was then switched from insulin therapy to oral medication with metformin 500 mg/d, empagliflozin 10 mg/d, and vildagliptin 100 mg/d. The patient's general condition improved, and she was discharged two days after switching to oral treatment when her one-point blood glucose level decreased to 203 mg/dL.

Two days after discharge from the medical practitioner's clinic, she consulted Mie University Hospital's outpatient department complaining of fatigue and vomiting. The clinical findings on examination were as follows: Height 159.3 cm; body weight 58.6 kg, body mass index 23.0 kg/m2, blood pressure 128/83 mmHg, heart rate 107 beats/min, body temperature 37.4 ˚C, and peripheral oxygen saturation (SpO2; normal level > 95%) at room air 98 %.

***History of past illness***

She had no medical history of any disease.

***Physical examination***

The patient's physical examination showed notable dryness of the oral cavity.

***Laboratory examinations***

Table 1 showed the results of the laboratory analysis performed at Mie University Hospital. Arterial blood gases demonstrated metabolic acidosis (pH, 7.18; pCO2, 18 mmHg; HCO3, 6.6 mEq/L; base excess, -19.3 mmol/L; A-gap, 27.6 mmol/L), with normal level of lactic acid (1.0 mmol/L). Fasting blood glucose (184 mg/dL) was mildly elevated with increased glycated hemoglobin/hemoglobin A1c (HbA1c) (7.3%). Urinalysis showed high levels of glucose (2000 mg/dL) and ketone bodies (3+). The plasma levels of 3-hydroxybutyric acid (6585 μmol/L) were markedly high. The renal function markers (blood urea nitrogen 9.1 mg/dL; serum creatinine 0.40 mg/dL) were within the normal range. These findings were compatible with the diagnosis of diabetic ketoacidosis with mild hyperglycemia.

***Further diagnostic work-up***

Additional laboratory analysis showed reduced urinary C-peptide level (8.6 μg/d) and decreased fasting serum C-peptide level (0.3 ng/mL). However, islet-related autoantibodies, including anti-glutamic acid decarboxylase antibody, insulin autoantibody, islet cell antibody, insulinoma-associated protein-2 antibody, and zinc transporter-8 autoantibody, were undetectable. An abdominal computed tomography showed a normal pancreas, and the blood level of pancreas exocrine enzymes, including amylase and lipase, were within the normal range.

**FINAL DIAGNOSIS**

We made the diagnosis of FT1DM based on the laboratory findings at Mie University Hospital and the severe hyperglycemia (≥ 16.0 mmol/L), and a mild increase in HbA1c (< 8.7%) observed at the medical practitioner's clinic.

**TREATMENT**

On the first day of hospitalization at Mie University Hospital, besides suspending oral antidiabetic agents, the patient received intravenous fluid infusion (1500 mL), including 20 g of dextrose and 2 units of regular insulin. After this treatment, her metabolic acidosis substantially (pH, 7.32; pCO2, 25.9 mmHg; HCO3− 12.9 mmol/L) improved. Because the patient had reduced blood potassium levels (2.8 mEq/L), 10 mEq/d potassium was administered together with 2000 mL/d of intravenous fluid infusion, including 60 g dextrose and 6 units of regular insulin. Blood glucose level fluctuated between 156 mg/dL and 195 mg/dL during the first two days after hospitalization. On the third day of hospitalization, oral food intake and multiple daily injections of insulin were initiated together with a gradual reduction in fluid administration. Urinary ketone bodies became negative on day 7.

**OUTCOME AND FOLLOW-UP**

The patient was discharged on day 14 with the therapeutic indication of subcutaneous injection of insulin glargine (18 U) before sleep and subcutaneous injection of insulin aspart (12U-6U-10U) before each meal.

**DISCUSSION**

F1DM is a severe subtype of type 1 diabetes mellitus characterized by extremely rapid and almost complete destruction of pancreatic β-cells that may eventually lead to diabetic ketoacidosis[1]. It was first reported in Japan by Imagawa *et al*[1], and since then, it has been mainly reported in East Asia. Approximately 20% of acute-onset type 1 diabetes in Japan is F1DM. The Committee of the Japan Diabetes Society reported the diagnostic criteria of FT1DM in 2012[1,2]. There are three criteria for the diagnosis of FT1DM: (1) Occurrence of diabetic ketoacidosis or ketosis soon (within seven days) after the onset of hyperglycemic symptoms, including elevation of urinary and serum ketone bodies during the first visit; (2) Plasma glucose level of ≥ 16.0 mmol/L (288 mg/dL) and HbA1c level of < 8.7% during the first visit; and (3) Urinary C-peptide excretion of < 10 μg/d or fasting serum C-peptide level of < 0.3 ng/mL (0.10 nM) and < 0.5 ng/mL (0.17 nM) after intravenous glucagon (or 2 h after a meal) load[3]. Circulating pancreatic islet-related autoantibodies are generally negative in FT1DM[1].

At the medical practitioner's clinic, the patient showed an extremely high blood glucose level and a slight increase of HbA1c with a trace of ketone bodies in urine. Symptoms improved after starting insulin therapy. Subsequent laboratory analysis showed a negative test for circulating anti-glutamic acid decarboxylase antibodies. Based on this negative test, the patient was wrongly diagnosed with type 2 diabetes mellitus. Therefore, insulin therapy was stopped, and oral administration of biguanide, dipeptidyl peptidase-4 inhibitor, and SGLT2 inhibitor was initiated. However, discontinuation of insulin and therapy with oral SGLT2 led to the development of diabetic ketoacidosis. During the first visit of the patient at the medical practitioner's clinic, the laboratory findings of severe hyperglycemia (≥ 16.0 mmol/L), a light increase of HbA1c (< 8.7%), and ketosis (urinary ketones) are compatible with the diagnosis of F1DM. However, the patient was not diagnosed with F1DM at the first clinic she consulted, probably because the data on C-peptide levels in blood and urine were unavailable. Once admitted to Mie University Hospital, laboratory analysis showed abnormal levels of urinary C-peptide, indicating a remarkable decrease of endogenous insulin secretion, thus strongly suggesting the diagnosis of F1DM. Pancreatic swelling and elevated blood levels of pancreatic enzymes have also been reported in patients with F1DM[4,5]. However, the pancreas CT findings and the blood levels of pancreas exocrine enzymes were normal. It is worth noting that in the present case, diabetic ketoacidosis occurred despite the slight increase in blood glucose level during the treatment with an SGLT2 inhibitor.

SGLT2 inhibitors are a new class of anti-hyperglycemic medications first introduced in 2013 to treat type 2 diabetes[6]. SGLT2 inhibitors lower the serum glucose levels by increasing urinary glucose clearance[6,7]. These therapeutic drugs may induce diabetic ketoacidosis[8]. In 2015, the United States Food and Drug Administration issued a warning statement regarding the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors[9]. Several mechanisms may explain the increase of blood ketone bodies by SGLT2 inhibitors. SGLT2 inhibitors stimulate glucagon secretion from pancreatic α cells by lowering blood glucose and binding directly to SGLT2 expressed in pancreatic α cells[10]. This hyperglucagonemia accelerates lipolysis leading to increased release of free fatty acids in the blood[8]. The amelioration of hyperglycemia by SGLT2 inhibitors also suppresses the endogenous secretion of insulin. Inhibition of hepatic acetyl-CoA carboxylase by the increased blood levels of glucagon and the decreased insulinemia decreases malonyl CoA, increases carnitine palmitoyl-transferase type I, and accelerates β-oxidation leading to enhanced production of ketone bodies from free fatty acids[8]. The significant reduction of endogenous insulin secretion observed in our current case further increases the risk of developing diabetic ketoacidosis. A normal or mildly elevated blood glucose level referred to as euglycemic diabetic ketoacidosis is another characteristic finding in diabetic ketoacidosis induced by SGLT2 inhibitors[11]. This laboratory finding makes the diagnosis of diabetic ketoacidosis even more difficult, and it is a frequent cause of missed diagnosis or delayed treatment. In our present case, the discontinuation of insulin therapy and administration of SGLT2 inhibitor might have contributed to the acceleration of diabetic ketoacidosis.

**CONCLUSION**

Here, we report a case of F1DM with diabetic ketoacidosis. This case report underscores the importance of considering the diagnosis of F1DM in all patients with severe hyperglycemia even in the absence of circulating autoantibodies and the possibility of euglycemic diabetic ketoacidosis in patients treated with SGLT2 inhibitors. SGLT2 inhibitors are frequently used as antidiabetic drugs for their cardiovascular[12-14] and renal benefits[15,16]. Recently, Japan approved the use of dapagliflozin and ipragliflozin in combination with insulin for type 1 diabetes, and in May 2020, the United States Food and Drug Administration approved the indication of dapagliflozin for heart failure. The major availability of SGLT2 inhibitors predicts an increase in the number of medical indications of SGLT2 inhibitors in the coming future. Therefore, major awareness of the potential adverse events of SGLT2 inhibitors is fundamental to avoid misdiagnosis in daily clinical practice.

**REFERENCES**

1 **Imagawa A**, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. *N Engl J Med* 2000; **342**: 301-307 [PMID: 10655528 DOI: 10.1056/NEJM200002033420501]

2 **Imagawa A**, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H. Fulminant type 1 diabetes: a nationwide survey in Japan. *Diabetes Care* 2003; **26**: 2345-2352 [PMID: 12882860 DOI: 10.2337/diacare.26.8.2345]

3 **Imagawa A**, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). *J Diabetes Investig* 2012; **3**: 536-539 [PMID: 24843620 DOI: 10.1111/jdi.12024]

4 **Kahara T**, Takamura T, Sakurai M, Misu H, Usuda R, Hayakawa T, Nishimura Y, Bando Y, Nagaoka T, Nagai Y, Kaneko S. Pancreatic exocrine and endocrine events occur concomitantly but independently during the course of fulminant type 1 diabetes. *Diabetes Res Clin Pract* 2006; **71**: 241-246 [PMID: 16112239 DOI: 10.1016/j.diabres.2005.07.003]

5 **Nakajima M**, Shirokawa M, Nakano T, Goto H. Fulminant type 1 diabetes mellitus with remarkable elevation of serum pancreatic enzymes. *Am J Emerg Med* 2018; **36**: 1326.e3-1326.e5 [PMID: 29685363 DOI: 10.1016/j.ajem.2018.04.026]

6 **Nair S**, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. *J Clin Endocrinol Metab* 2010; **95**: 34-42 [PMID: 19892839 DOI: 10.1210/jc.2009-0473]

7 **Tahrani AA**, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. *Lancet* 2011; **378**: 182-197 [PMID: 21705062 DOI: 10.1016/S0140-6736(11)60207-9]

8 **Ogawa W**, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. *J Diabetes Investig* 2016; **7**: 135-138 [PMID: 27042263 DOI: 10.1111/jdi.12401]

9 **U.S. Food and Drug Administration.** FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, 2015. [cited 10 October 2020] Available from: https://www.fda.gov/downloads/drugs/drugsafety/ucm446954.pdf

10 **Bonner C**, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat Med* 2015; **21**: 512-517 [PMID: 25894829 DOI: 10.1038/nm.3828]

11 **Peters AL**, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care* 2015; **38**: 1687-1693 [PMID: 26078479 DOI: 10.2337/dc15-0843]

12 **Neal B**, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 2017; **377**: 2099 [PMID: 29166232 DOI: 10.1056/NEJMc1712572]

13 **Wiviott SD**, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2019; **380**: 347-357 [PMID: 30415602 DOI: 10.1056/NEJMoa1812389]

14 **Zinman B**, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015; **373**: 2117-2128 [PMID: 26378978 DOI: 10.1056/NEJMoa1504720]

15 **Perkovic V**, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol* 2018; **6**: 691-704 [PMID: 29937267 DOI: 10.1016/S2213-8587(18)30141-4]

16 **Wanner C**, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med* 2016; **375**: 323-334 [PMID: 27299675 DOI: 10.1056/NEJMoa1515920]

**Footnotes**

**Informed consent statement:** Written informed consent was obtained from the patient to publish clinical details and images when she was alive.

**Conflict-of-interest statement:** Yano Y reports receiving lecture fees from Novo Nordisk; and Gabazza EC received grants from Shionogi Corporation and Asahi Kasei. Other authors declared no conflict of interest concerning this case report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** December 8, 2020

**First decision:** January 24, 2021

**Article in press:** March 11, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Anyfantakis D **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Laboratory data**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Blood cell count** |  | **Normal range** | **Units** | **Biochemical examination** |  | **Normal range** | **Units** | **Arterial blood gas analysis (room air)** |  | **Normal range** | **Units** |
| White blood cell | 11440 | 3300-8600 | /μL | Total protein | 8.2 | 6.6-8.1 | g/dL | pH | 7.182 | 7.350-7.450 | mmHg |
| Red blood cell | 489 | 386-492 | × 104/μL | Albumin | 4.5 | 4.1-5.1 | g/dL | paCO2 | 18 | 35.0-45.0 | mmHg |
| Hemoglobin | 14.7 | 11.6-14.8 | g/dL | BUN | 9.1 | 8.0-20.0 | mg/dL | paO2 | 115.2 | > 80 | mmol/L |
| Hematocrit | 43.6 | 35.1-44.1 | % | Creatinine | 0.4 | 0.46-0.79 | mg/dL | HCO3- | 6.6 | 22.0-26.0 | mmol/L |
| Platelet | 28.3 | 15.8-34.8 | × 104/μL | Uric acid | 5.3 | 2.6-5.5 | mg/dL | Base excess | -19.3 | -2.0-+2.0 | mmol/L |
|  |  |  |  | Na | 131 | 138-145 | mEq/L | Anion gap | 27.6 | 10.0-18.0 | mmol/L |
| Urinalysis |  |  |  | K | 4.5 | 3.6-4.8 | mEq/L | Lactic acid | 1.0 | 0.9-1.7 | mmHg |
| Specific gravity | 1.015 | 1.005-1.030 |  | Cl | 102 | 101-108 | mEq/L |  |  |  |  |
| pH | 5.5 | 4.5-7.5 |  | Ca | 8.7 | 8.8-10.1 | mg/dL | Blood ketone bodies |  |  |  |
| Glucose | 2000 | < 50 | mg/dL | P | 2.6 | 2.7-4.6 | mg/dL |  Acetoacetate | 1784 | < 55 | μmol/L |
| Protein | 100 | < 30 | mg/dL | AST | 20 | 13-30 | U/L |  3-Hydroxybutyrate | 6585 | < 85 | μmol/L |
| Ketone body | (3+) | (-) |  | ALT | 6 | 7-23 | U/L |  |  |  |  |
| Blood | (±) | (-) |  | LDH | 251 | 124-222 | U/L | Autoantibodies |  |  |  |
|  |  |  |  | γ-GTP | 43 | 9-32 | U/L | GAD autoantibody | < 5.0 | < 5.0 | U/mL |
| Diabetic parameters |  |  |  | ALP | 178 | 106-322 | U/L | IA-2 autoantibody | < 0.6 | < 0.6 | U/mL |
| HbA1c | 7.3 | 4.9-6.0 | % | T-Bil | 0.5 | 0.4-1.5 | mg/dL | Insulin autoantibody | < 0.4 | < 0.4 | U/mL |
| Glycoalbumin | 23.2 | 11.0-16.0 | % |  CRP | 0.12 | < 0.14 | mg/dL | Islet cell antibody | (-) | (-) |  |
| Blood glucose | 184 | 73-109 | mg/dL | Total-cholesterol | 242 | 142-248 | mg/dL | ZnT8 autoantibody | < 10.0 | < 15.0 | U/mL |
| Serum C-peptide | 0.3 | 0.6-2.1 | ng/mL |  Triglyceride | 230 | 30-117 | mg/dL |  |  |  |  |
| Urine C-peptide | 8.6 | 22.8-155.2 | μg/d |  Amylase | 35 | 44-132 | U/L |  |  |  |  |
|  |  |  |  |  Lipase | 23 | 12-51 | U/L |  |  |  |  |

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; T-Bil: Total bilirubin; CRP: C-reactive protein; GAD: Glutamic acid decarboxylase; IA-2: Insulinoma-associated protein-2; BUN: Blood urea nitrogen; LDH: Lactate dehydrogenase; HbA1c: Glycated hemoglobin/hemoglobin A1c.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**